Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Intangibles (2022 - 2025)

Historic Intangibles for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to $15.4 million.

  • Arcutis Biotherapeutics' Intangibles rose 5701.59% to $15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year increase of 5701.59%. This contributed to the annual value of $9.5 million for FY2024, which is 4723.52% up from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Intangibles is $15.4 million, which was up 5701.59% from $15.9 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Intangibles ranged from a high of $16.5 million in Q1 2025 and a low of $6.1 million during Q2 2024
  • For the 4-year period, Arcutis Biotherapeutics' Intangibles averaged around $9.3 million, with its median value being $7.2 million (2022).
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Intangibles plummeted by 1099.53% in 2024, and later skyrocketed by 16400.0% in 2025.
  • Quarter analysis of 4 years shows Arcutis Biotherapeutics' Intangibles stood at $7.2 million in 2022, then decreased by 10.43% to $6.4 million in 2023, then surged by 47.24% to $9.5 million in 2024, then soared by 62.2% to $15.4 million in 2025.
  • Its last three reported values are $15.4 million in Q3 2025, $15.9 million for Q2 2025, and $16.5 million during Q1 2025.